Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 9/20 | 0.49 |
| ▸ | KAT8 | Q9H7Z6 | 8/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439715 | 0.85 | BDKRB1 (0.67) | BDKRB1 | |
| SCHEMBL4844745 | 0.81 | BDKRB1 (0.75) | BDKRB1 | |
| SCHEMBL13063104 | 0.80 | BDKRB1 (0.48) | BDKRB1KAT8KAT6AMAPK1MEN1 | |
| SCHEMBL15372673 | 0.76 | BDKRB1 (0.41) | BDKRB1MAPK1MEN1KMT2ANPC1 | |
| SCHEMBL3440159 | 0.75 | BDKRB1 (0.66) | BDKRB1 | |
| SCHEMBL14304352 | 0.73 | BDKRB1 (0.61) | BDKRB1 | |
| SCHEMBL3440102 | 0.72 | BDKRB1 (0.50) | BDKRB1 | |
| SCHEMBL4780362 | 0.71 | BDKRB1 (0.40) | BDKRB1 | |
| SCHEMBL3440243 | 0.70 | BDKRB1 (0.65) | BDKRB1 | |
| SCHEMBL3439852 | 0.69 | BDKRB1 (0.69) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294775-A1 | NOVEL COMPOUNDS | TRPV1, OPRL1, TRPA1 | BDKRB1 80/4885KAT8 2753/4885KAT6A 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.